Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

The festive season may be a chance to rest up and recharge—but tell that to biotech dealmakers, who have been as busy as ever ...

（原标题：科伦药业：控股子公司抗PD-L1塔戈利单抗获批上市） 证券时报e公司讯，科伦药业(002422)1月1日晚间公告，公司控股子公司四川科伦博泰生物医药股份有限公司用于治疗既往接受过2线及以上化疗失败的复发或转移性鼻咽癌患者的靶向程序性细胞死亡配体1(PD-L1)的创新人源化单克隆抗体(简称“单抗”)塔戈利单抗(前称KL-A167)(科泰莱®)已获国家药监局批准于中国上市。

Envafolimab is under clinical development by Alphamab Oncology and currently in Phase I for Non-Small Cell Lung Cancer.

Envafolimab is under clinical development by Alphamab Oncology and currently in Phase I for Head And Neck Cancer.

The decision follows a similar one in the US and is due to the drug's failure to significantly improve overall survival versus chemo in the TROPION-Lung01 trial.

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In ...

Tevimbra is already approved in the US for the treatment of unresectable or metastatic oesophageal squamous cell carcinoma ...

Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...